News

Cantech Letter39m
CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM
CNW/ – This week, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial ...
pharmaphorum59m
Novo Nordisk's fling with Hims & Hers ends in a bust-up
In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass ...